Tilray, Inc.: management transactions · United States · SEC (Form 4)

About Tilray, Inc.

Tilray, Inc. (NASDAQ: TLRY) is a U.S.-listed company traded on the NASDAQ market in the United States. Its operating footprint spans the United States, Canada, Europe, Australia, and Latin America, with corporate and operational hubs reported in New York and Leamington, Ontario. For international investors, Tilray should be viewed as a hybrid consumer platform rather than a pure cannabis operator: the company began in medical cannabis and has evolved into a branded lifestyle and consumer packaged goods business centered on cannabis, beverage alcohol and non-alcoholic drinks, hemp-based products, and wellness. Tilray was founded in the late 2010s, during the early wave of North American cannabis legalization and medical-market expansion. Since then, the company has pursued an acquisition-led strategy to build scale and broaden its revenue base. In recent company communications, Tilray describes itself as supporting more than 40 brands across more than 20 countries. That brand portfolio gives the group exposure to several adjacent categories: medical cannabis, adult-use cannabis where permitted, hemp foods, craft beer, non-alcoholic beer, hemp-derived THC beverages, and wellness products. Tilray Medical remains an important pillar, with international distribution of therapeutic cannabis products. From a competitive standpoint, Tilray operates in highly fragmented but regulation-sensitive markets. In cannabis, the company aims to leverage its international platform, manufacturing capabilities, and regulatory experience to compete in both medical and emerging adult-use categories. In beverages, Tilray has been building a larger craft and alternative-beverage platform through acquisitions and distribution expansion, seeking to strengthen its position in North America and selectively in overseas markets. Its key products and services include cannabis flower and extracts, medical cannabis offerings, craft beers, non-alcoholic beers, hemp-derived THC drinks, hemp-based food products, and consumer wellness brands. Recent developments underscore the company’s diversification strategy. In 2025 and 2026, Tilray highlighted growth in non-alcoholic beer and hemp-derived THC beverages, the launch and expansion of Tilray Medical USA following changes in the U.S. federal cannabis backdrop, and multiple beverage acquisitions, including strategic BrewDog assets in the United States, the United Kingdom, and Australia. Tilray has also emphasized expansion opportunities in Europe, the Middle East, India, Türkiye, and Asia. For investors, the company remains a speculative growth story: it offers broader diversification than a typical cannabis pure play, but it is still exposed to regulatory uncertainty, execution risk, and the competitive intensity of consumer packaged goods markets.